Philip Mease
0000-0002-6620-0457
19 papers found
Refreshing results…
Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and disease characteristics: pooled results through week 52 of two phase III, randomised, placebo-controlled studies
Treatment Responses in Patients With Psoriatic Arthritis Axial Disease According to Human Leukocyte Antigen‐B27 Status: An Analysis From the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
Plain Radiographic Instruments for Structural Damage in Peripheral Joints in Psoriatic Arthritis: A Report From the GRAPPA-OMERACT Working Group
Long‐Term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin‐23, Through Two Years: Results From a Phase III , Randomized, Double‐Blind , Placebo‐Controlled Study Conducted in Biologic‐Naive Patients With Active Psoriatic Arthritis
Performance and Predictors of Minimal Disease Activity Response in Patients With Peripheral Spondyloarthritis Treated With Adalimumab
Domains to Be Considered for the Core Outcome Set of Axial Spondyloarthritis: Results From a 3-round Delphi Survey
Comparative effectiveness of guselkumab in psoriatic arthritis: results from systematic literature review and network meta-analysis
Efficacy and Safety of Guselkumab, an Interleukin‐23p19–Specific Monoclonal Antibody, Through One Year in Biologic‐Naive Patients With Psoriatic Arthritis
Instruments Measuring Physical Function for Psoriatic Arthritis Endorsed at GRAPPA 2020 Annual Meeting: Updates of the GRAPPA-OMERACT Working Group
Evaluation of Improvement in Skin and Nail Psoriasis in Bio‐naïve Patients With Active Psoriatic Arthritis Treated With Golimumab: Results Through Week 52 of the GO‐VIBRANT Study
Measuring Outcomes in Psoriatic Arthritis
Performance of composite measures used in a trial of etanercept and methotrexate as monotherapy or in combination in psoriatic arthritis
Methotrexate in Psoriasis and Psoriatic Arthritis
The GRAPPA-OMERACT Working Group: 4 Prioritized Domains for Completing the Core Outcome Measurement Set for Psoriatic Arthritis 2019 Updates
GRAPPA 2019 Project Report
Outcomes of the 2019 GRAPPA Workshop on Continuous Composite Indices for the Assessment of Psoriatic Arthritis and Membership-recommended Next Steps
Treatment‐to‐Target With Apremilast in Psoriatic Arthritis: The Probability of Achieving Targets and Comprehensive Control of Disease Manifestations
Appraisal of candidate instruments for assessment of the physical function domain in patients with psoriatic arthritis
GRAPPA 2018 Project Report
Missing publications? Search for publications with a matching author name.